More than one in 10 adults receiving inappropriate aspirin therapy for cardio disease

14 January 2015

More than one in 10 US adults are receiving inappropriate aspirin therapy for the primary prevention of cardiovascular disease, according to research published in the Journal of the American College of Cardiology.

In people given a low daily dose of aspirin unnecessarily, the chances of them suffering a stroke or myocardial infarction were not high enough to outweigh risks, which include serious gastrointestinal bleeding.

The study, which comprised 60,808 participants from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry, looked at patients receiving aspirin for primary prevention of CVD. Results showed the frequency of inappropriate aspirin use (those with a 10-year CVD risk under 6%) was 11.6%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK